What is HelixBind?
HelixBind is at the forefront of revolutionizing bloodstream infection diagnostics and management with its proprietary technology. The platform delivers rapid, accurate microbiology results, empowering clinicians to swiftly identify invasive infections and personalize antimicrobial treatments. This enhanced diagnostic capability is crucial for combating antimicrobial resistance and improving patient outcomes, particularly for those suffering from sepsis and other critical bloodstream infections.
How much funding has HelixBind raised?
HelixBind has raised a total of $4.2M across 2 funding rounds:
Unspecified
$4M
Debt
$150K
Unspecified (2019): $4M with participation from Carb-X
Debt (2020): $150K led by PPP
Key Investors in HelixBind
Carb-X
CARB-X is a global accelerator focused on combating dangerous drug-resistant bacteria by supporting the development of new antibiotics and life-saving products. They invest in early-stage antibiotics, diagnostics, and other solutions to prevent, diagnose, and treat bacterial infections.
PPP
Public-Private Partnership
What's next for HelixBind?
The recent major enterprise-level funding positions HelixBind for accelerated growth and market penetration. This capital infusion is expected to fuel further development of its innovative diagnostic platform, expand its reach within the healthcare provider sector, and solidify its role in the fight against antimicrobial resistance. The company's strategic focus on improving diagnostic speed and accuracy aligns with the growing global imperative to optimize antibiotic stewardship and enhance patient care pathways.
See full HelixBind company page
